Product Images Rocuronium Bromide

This is a table displaying the dose of Rocuronium Bromide administered to different groups of patients and the corresponding percentage of patients who experienced excellent or good intubating conditions within a certain time frame after administration. The first group (adults aged 18-64 years) was administered doses of 0.45 mg/kg or 0.6 mg/kg over 5 seconds, with 6% and 9% of patients, respectively, experiencing excellent or good intubating conditions within 16 minutes. The second group (infants aged 3 months to 1 year) was administered a dose of 0.6 mg/kg, with all 18 patients experiencing excellent or good intubating conditions within 100 seconds. The third group (pediatric patients aged 1-12 years) was administered a dose of 0.6 mg/kg, with all 12 patients experiencing excellent or good intubating conditions.*

This appears to be a table containing information about the dose and time to achieve various levels of muscle relaxation after administration of Rocuronium Bromide in different age groups of patients, from neonates to adolescents. The table includes the dose given in mg/kg, the time to maximum block and the time to reappearance of muscle function, measured in seconds and minutes. No other context is available.*

The text appears to be a figure caption or a part of a research article, which describes the relation between the duration of clinical effect and the initial dose of Rocuronium Bromide by age group. A graph is displayed showing the median, 25th and 75th percentile, and individual values in the age group of 18-64 years and those above 65 years. The data is given in milligrams per kilogram.*

The figure shows the relationship between the duration of the clinical effect and the number of maintenance doses of rocuronium bromide at different doses. The duration is measured in minutes. The sample size is 13 for one group and 2 for another. There is not enough information to determine what the units are for the dose axis.*

This appears to be a table comparing PK parameters in patients with normal renal function, renal transplants, hepatic dysfunction, and hepatic function. The parameters include clearance, volume of distribution, steady state, and elimination for various drugs or substances. The values are presented in different units for each group of patients. However, the output is difficult to read and interpret accurately.*

This appears to be a table of pharmacokinetic (PK) parameters related to patient age ranges. The age ranges are organized into three categories: less than 3 months old, between 1 and 3 years old, and over 3 years old. The table lists values for clearance, volume of distribution, and elimination, but there is no further context to explain what these values represent.*

The text is a set of three tables presenting infusion rates using Rocuronium Bromide Injection for different strengths of the medication. The tables show the delivery rate (in mcg/kg/min) based on the patient's weight and the corresponding infusion delivery rate (in mL/hr) for each infusion strength. The tables are useful for determining the appropriate infusion rate of Rocuronium Bromide Injection based on a patient's weight.*

This appears to be a product label for a medication called "Rocuronium Bromide Injection". It is a paralyzing agent that should only be used for intravenous use. The label also contains important information regarding dosage, manufacturer and the National Drug Code (NDC) which helps with identifying the product.*

This is a warning label for a drug called Rocuronium, which is a paralyzing agent that can cause respiratory arrest. Facilities must have artificial respiration available. It's a sterile and nonpyrogenic drug that should be stored in a refrigerator between 2-6°C and not frozen. It's recommended to use open vials within 30 days and to use the drug within 60 days after being removed from refrigeration. The drug is available in a 5mL multiple-dose vial and is for intravenous use only.*

This text provides important warning and usage information for the drug Rocuronium, which is a paralyzing agent that can cause respiratory arrest. Facilities must have the necessary equipment and expertise for artificial respiration readily available when administering this drug. The drug should be stored in a refrigerator between 2°C to 6°C and should not be frozen. Once removed from refrigeration, it should be used within 60 days and opened vials should be used within 30 days. The text also indicates the code and manufacturer of the drug. Therefore, this text would be useful for medical professionals who may prescribe, dispense, or administer Rocuronium.*